Hemostemix has drafted the protocol for a Phase I clinical trial to test VesCell™, its autologous stem cell therapy, for longevity and healthspan improvement beyond cardiovascular diseases. The trial aims to assess VesCell™'s effects on quality of life, muscle mass, cognition, immune health, and physical function. Previous studies showed significant improvements in heart function, walking capacity, and quality of life in patients with heart conditions. The company plans regulatory submissions and clinical site activations next, targeting competitions that fund innovations in healthy aging.
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...
Maurizio Mian, known as the pioneer of influencer culture, has launched a new micro-drama series called 'The Experiment.' The show features popular social media personalities living in luxury while exploring whether happiness can be measured and incr...
The global wealth management software market, valued at $6.28 billion in 2025, is projected to reach $18.77 billion by 2033, growing at a 14.7% CAGR. Growth is fueled by rising adoption of AI, automation, and digital advisory tools that enhance workf...
